{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-004825","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.319120+00:00","generated_at":"2026-06-27T07:16:48.252504+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncotelic extends JV term sheet standstill with GMP to March 31, 2022","bullets":["Extended standstill provisions of JV term sheet with Golden Mountain Partners to March 31, 2022.","JV intended to develop Oncotelic's drug portfolio and build a manufacturing facility.","Company previously announced plan to take the JV public via IPO at a future date.","Extension allows additional time to complete the transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-004825","json":"https://secwatch.observer/filing/0001493152-22-004825.json","markdown":"https://secwatch.observer/filing/0001493152-22-004825.md","text":"https://secwatch.observer/filing/0001493152-22-004825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222004825/0001493152-22-004825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222004825/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:16:48.252504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}